Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of NEO-PTC-01 in advanced or metastatic melanoma
NL-OMON52586Phase 1Recruiting
- Sponsor
- BioNTech SE
- Start
- Dec 2020
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BNT221 in melanoma, sponsored by BioNTech SE. Primary endpoints: Safety and tolerability, Highest tolerable dose and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
BNT221
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON52586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52586.